Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer

BackgroundThe emergence of HER2 antibody-drug conjugates provides new treatment decisions for breast cancer patients, especially those with HER2-low expression. In order to explore the biological characteristics of breast cancer with HER2-low expression, the HER2-low category in primary breast cance...

Full description

Bibliographic Details
Main Authors:	Jiuyan Shang, Xuemei Sun, Zihang Xu, Lijing Cai, Chang Liu, Si Wu, Yueping Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Oncology
Subjects:	breast cancer human epidermal growth factor receptor 2 hormone receptor neoadjuvant therapy pathological complete response
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1086480/full

Similar Items

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
by: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Published: (2023-07-01)

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
by: Hai-long Chen, et al.
Published: (2023-09-01)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
by: Wei Chen, et al.
Published: (2023-10-01)

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
by: Xiaoyu Liu, et al.
Published: (2023-09-01)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
by: Jiayi Li, et al.
Published: (2022-02-01)

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
by: LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun
Published: (2023-04-01)

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
by: He Dou, et al.
Published: (2024-01-01)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
by: Libo Yang, et al.
Published: (2018-03-01)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
by: Yifan Xie, et al.
Published: (2021-06-01)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
by: Guoshuang Shen, et al.
Published: (2021-07-01)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
by: Jiujun Zhu, et al.
Published: (2022-09-01)

Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
by: Abdullah Evren YETİŞİR, et al.
Published: (2021-08-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2024-02-01)

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
by: Dandan Guan, et al.
Published: (2022-09-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
by: Jung Hwan Ji, et al.
Published: (2023-01-01)

Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China
by: Dong-Mei Peng, et al.
Published: (2024-04-01)

Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
by: Lingfeng Tang, et al.
Published: (2022-01-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: In Hee Lee, et al.
Published: (2020-11-01)

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
by: MA Xiangmin, et al.
Published: (2022-01-01)

Advances in the diagnosis of pathological response by a second biopsy in breast cancer neoadjuvant therapy and their clinical significance
by: XU Bingqi, ZHANG Guoqiang
Published: (2022-04-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
by: Lingfeng Tang, et al.
Published: (2022-12-01)

Complete pathological response following neoadjuvant chemoradiotherapy in locally advanced colorectal carcinoma
by: Ozana Miličević, et al.
Published: (2022-01-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
by: Yoshitaka Shimamaki, et al.
Published: (2024-02-01)

The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
by: G A Frank, et al.
Published: (2015-06-01)

Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI
by: Jiali Zhou, et al.
Published: (2020-02-01)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
by: Yan Hu, et al.
Published: (2022-04-01)

Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment
by: Hsu-Huan Chou, et al.
Published: (2021-03-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
by: Ling-Ming Tseng, et al.
Published: (2023-12-01)

Real-world Efficacy and Safety Comparison of Neoadjuvant Treatment of HER2-positive Breast Cancer with TCbHP Versus AC-THP
by: GENG Dan, et al.
Published: (2023-08-01)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
by: Fu Li, et al.
Published: (2023-01-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
by: Witali Aswolinskiy, et al.
Published: (2023-11-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01)

Pathology after neoadjuvant treatment – How to assess residual disease
by: Giuseppe Viale, et al.
Published: (2022-03-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
by: Lucas MW, et al.
Published: (2022-08-01)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
by: Ailin Lan, et al.
Published: (2022-08-01)